Background: Memory suppression transiently disrupts hippocampal activity, leading to suppression-induced forgetting (SIF), especially for negative stimuli. However, traditional paradigms like Think/No-Think rely on explicit control and lack ecological validity. This study introduces a #Game-based task that implicitly elicits suppression through reversed motor mappings, providing a naturalistic approach to studying memory inhibition. Objective: To examine how shadow-induced forgetting (ShIF) varies across short-term and long-term intervals (0h, 24h, 72h), under conscious versus unconscious exposure, and between positive and negative emotional stimuli. Methods: This single-center, within-subjects experimental study involved 56 university students (mean age = 23.37 ± 1.84 years) and was conducted between December 1, 2023, and March 1, 2024. Participants learned 36 cue–target image pairs varying in emotional valence (positive, negative). They underwent a #Game-based paradigm where habitual motor responses were disrupted through reversed key mappings to induce an amnesic shadow. During #Gameplay, selected cues were presented either consciously or unconsciously, while others served as controls. Memory performance was assessed using METEOR scores (semantic similarity) immediately after intervention (0 h), and again at 24 h and 72 h. Electroencephalography (EEG) was recorded in a subset of 40 participants to examine neural correlates of memory suppression. Results: Shadow-Induced Forgetting (ShIF) effects were short-term, conscious-dependent, and selective for negative memories. A significant interaction between exposure condition and time (F₃.₆₂,₁₉₉.₃₃ = 2.7, P=.037, η²ₚ = 0.05, 95% CI [0.00, 1.00]) indicated that the effect varied across time points. Specifically, a significant ShIF effect emerged immediately after the intervention (0h) in the conscious condition (t = −2.86, P= .018, d = 0.38) but was absent in the unconscious condition, and dissipated by 72 hours. Robust main effects of time (F₂,₁₀₉.₉₉ = 102.91, P

US Nonclinical Homecare Software Market share register 645.60 USD Million in 2024, projected to grow 8.35 % CAGR to reach USD Million 1559.85 during the forecast period 2025 - 2035.

Miricorilant is a novel selective glucocorticoid receptor (GR) modulator with mixed agonist/antagonist effects at the GR and modest antagonism at the mineralocorticoid receptor that is being develope...

Earlier this week, the U.S. Senate unanimously passed the FDA Modernization Act 3.0. This bill will require the FDA to update its regulations to replace references to “animal” testing with “nonclinica...

Rep. Buddy Carter, Serving Georgia's 1st District

US Nonclinical Homecare Software Market share register 645.60 USD Million in 2024, projected to grow 8.35 % CAGR to reach USD Million 1559.85 during the forecast period 2025 - 2035.

Simulations Plus (Nasdaq: SLP) on December 9, 2025 positioned its validated modeling engines and AI-orchestrated ecosystem to respond to the FDA's draft guidance on streamlined nonclinical safety studies for monospecific monoclonal antibodies. The company highlights integration of PBPK (GastroPlus), QST/QSP (BIOLOGXsym), and population modeling (MonolixSuite) to support weight-of-evidence assessments and reduced animal testing.Simulations Plus plans continued biologics modeling enhancements and frames its tools as aligned with FDA emphasis on mechanistic, model-informed nonclinical decision-making.

The U.S. Food and Drug Administration (FDA) on Dec. 2, 2025, issued its draft guidance on Monoclonal Antibodies: Streamlined Nonclinical Safety...

The U.S. Food and Drug Administration (FDA) on Dec. 2, 2025, issued its draft guidance on Monoclonal Antibodies: Streamlined Nonclinical Safety...

The U.S. Food and Drug Administration (FDA) on Dec. 2, 2025, issued its draft guidance on Monoclonal Antibodies: Streamlined Nonclinical Safety...